Market Trends of Global Premenstrual Syndrome Treatment Industry
This section covers the major market trends shaping the Premenstrual Syndrome Treatment Market according to our research experts:
Analgesic Drug Segment is Expected to Show Significant Growth During the Forecasts Period
Analgesics, also known as painkillers or pain relievers, are drugs that help in relieving pain without affecting consciousness, altering sensory perception, or blocking nerve impulse conduction. These analgesics are generally used to reduce PMS symptoms such as stomach cramps, headache, muscle pain, joint pain, and others. According to a study published in the National Health Institute in 2020, among all the analgesics used for the treatment of Premenstrual syndrome, diclofenac was the most commonly used analgesic followed by ibuprofen, ketoprofen, naproxen, aspirin, and placebo. As analgesics are the most effective treatment in premenstrual treatment, it is expected to drive market growth.
According to the article published in National Health Institute 2021, Analgesic is used in the treatment of PMS, including nonsteroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid and ibuprofen. NSAIDs reduce inflammation, relieve pain, and block the production of prostaglandin. Similarly, according to the report published in the United States Library of Medicine in 2020, 45 % of women worldwide were self-medicated and taking analgesics to relieve the pain associated with premenstrual syndrome.
A large number of women are affected by premenstrual syndrome and cannot afford to reach a hospital to check up on every month and need the analgesics products quickly raise the demand for this segment. Furthermore, most women are preferring self-medication without consulting a doctor. As the demand for this segment grows, market participants in the segment tend to focus more on the launch of new products. For example, in 2020, Bayer launched Midol, a multi-symptom pain reliever analgesic. Because of the rising prevalence of PMS, as well as the affordability and availability of analgesics, the market is expected to grow rapidly during the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecasts Period
North America is expected to hold a major market share in the global premenstrual syndrome treatment market due to an increase in the prevalence and awareness of premenstrual syndrome in females in this region. Hence, the incidence of treatment is also predicted to be high. For instance, a study published in the Indian Journal of Research in 2020, in the United States 2 billion dollars or 600 million working hours lost yearly due to the symptoms of Premenstrual syndrome. According to the Women's Health Concern and British Menopause Society in 2020, about 80% of reproductive women experience premenstrual syndrome pain at some stage in their lifetime. Most women experience some discomfort during pre-menstruation, especially one week before. But in 5%-10% of women, the pain is severe enough to disrupt their life.
Additionally, rising approval is also likely to fuel the market growth as in March 2019, Brexanolone was approved in the United States for the treatment of postpartum depression (PPD) a complication associated with premenstrual syndrome, the first drug approved by the United States Food and Drug Administration (FDA) specifically for PPD in adult women. Furthermore, increasing the approval of premenstrual syndrome therapy and increasing research and development activity for developing innovative drugs and well-established healthcare infrastructure is also fuelling the overall North American market to great extent.
